Compare Mondaycom Ltd (MNDY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Organon & Co. Common Stock — how do they compare? Mondaycom Ltd trades at $86.06 (market cap $3.70B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Mondaycom Ltd and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Organon & Co. Common Stock for 0 Days on average.
| MNDY | OGN | |
|---|---|---|
Market Cap | $3.70B | $3.61B |
Volume | 948,435 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $205.24 | $13.81 |
52-Week Low | $58.81 | $5.70 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $2.87B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $84.69, showing minimal daily movement (-0.08%) with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust revenue growth from $1.23B to $1.4B. Recent news highlights AI integration at Elevate '26 conference and inclusion in multiple growth stock lists, while technical indicators show mixed signals with RSI at neutral levels and key support at $83.
The stock presents a compelling growth story with 61.5% analyst buy ratings and a $108.64 consensus target offering 28% upside. However, elevated valuation multiples (P/E 35.83, EV/EBITDA 50.12) and competitive pressures from Meta's enterprise software push pose risks. Net cash flow turned negative in 2026 (-$737M) despite strong operating performance, requiring monitoring of capital allocation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
